Lynkuet Gains EU Approval for Menopause Symptom Relief

Under the brand name Lynkuet, elinzanetant has been authorized for marketing in the European Union (EU) by the European Commission. The medication is authorized for the management of moderate to severe vasomotor symptoms (VMS; also called hot flashes) brought on by menopause or adjuvant endocrine therapy (AET) for breast cancer.

“The European approval of Lynkuet brings a new option to women whose daily lives are disrupted by vasomotor symptoms,” said Christine Roth, executive vice president, global product strategy and commercialization, and member of the pharmaceutical leadership team at Bayer.

 “We understand how challenging and isolating these symptoms can be, often interfering with daily rhythm, personal productivity, and overall quality of life. Our commitment is to support women with solutions that truly address their needs, helping them feel like them themselves again by supporting healthcare and wellbeing at every stage.”

Also Read: Merck Reports Positive Phase 2 Results for Winrevair

1.2 billion women worldwide are predicted to go through menopause by 2030. Up to 80% of women experience VMS during the menopausal transition. About 40% of women in Europe report having moderate to severe VMS, underscoring the significant impact these symptoms have on day-to-day functioning and general wellbeing.

“Menopause symptoms, including hot flashes, can greatly affect women's quality of life,” said Nick Panay, Principal Investigator for OASIS-3, Consultant Gynecologist, Imperial College Healthcare NHS Trust, Professor of Practice, Imperial College London and Immediate Past President of the International Menopause Society.

“This approval is an important milestone in the area of menopause care as it expands therapeutic options for women experiencing distressing menopause symptoms with a novel targeted hormone-free treatment and facilitates healthcare professionals to achieve more personalized treatment.”